我国药品注册优先审评程序设计研究
2018-06-20冯媛媛杨悦
冯媛媛 杨悦
[摘要] 药品审评的质量和效率关系着整个药品上市进程。本文以药品注册优先审评程序为主线,基于我国药品审评实践,借鉴美国优先审评模式的成功经验,对比我国和美国的具体程序设计,找出我国程序设计的缺陷和不足,提出完善我国药品注册优先审评程序的相关建议,为药品注册优先审评制度建设提供可行性参考。
[关键词] 优先审评;药品注册;审评制度;程序设计
[中图分类号] R95 [文献标识码] A [文章编号] 1673-7210(2018)04(c)-0172-05
Design and study on priority review procedure of drug registration in China
FENG Yuanyuan1,2 YANG Yue1
1.School of Business Administrator, Shenyang Pharmaceutical University, Liaoning Province, Shenyang 110016, China; 2.People′s Medical Publishing House Co., Ltd., Beijing 100021, China
[Abstract] The quality and effectiveness of drug review is associated with the total procedure of drugs. Based on the practice of drug review in China and lessons from the successful experience of priority review in the United States, this paper takes the priority review procedure of drug registration as the main line. The defects and shortcomings are found out by comparing the procedure design of China with the one of the United States. Furthermore, this paper puts forward related suggestions to improve the priority review procedure of drug registration in China, and provides references for the construction of priority review system of drug registration.
[Key words] Priority review; Drug registration; Review system; Procedure design
新药研发上市情况是国家医药科技综合水平的重要标志,也是提升一国医疗水平的重要手段。作为由政府部门主导的作用于药品研发到上市过程的重要一环,药品审评的质量和效率关系着整个药品上市进程。为鼓励临床急需药品的创新研发、加快上市,美国于20世纪90年代首先建立了药品注册优先审评制度,经历20多年的实践和不断完善,已经形成一套成熟的全流程动态的审评制度体系。为解决严重药品注册申请积压、鼓励药品创新研发,我国于2016年建立并实施了药品注册优先审评制度。制度实施以来,取得了较好成果,审评审批效率提升,药品注册积压情况改善,但效果未达预期,主要归因于药品注册优先审评制度体系的不健全和审评程序设计缺陷。本文将以药品注册优先审评程序为主线,对比我国和美国的优先审评程序,找出我国程序缺陷,并基于我国审评实践,借鉴美国成功经验,提出完善我国药品注册优先审评程序的建议,为药品注册优先审评制度建設提供可行性参考。……
